Skip to main content

Market Research Outlook

MRO Tracker · Pharma

A selection of recent US generic drug approvals disclosed by Indian companies, with the brand they copy, any exclusivity, and each company's running approval count. This is a curated log of notable approvals, not a complete list of every approval, and it grows as companies disclose new ones.

9selected approvals logged, Aug to Nov 2026
3with exclusivity or first to file status
599Aurobindo's cumulative ANDA approvals
458Zydus approvals to date
MRO View: The mix is moving toward harder products. Recent wins include a transdermal patch, a nasal spray, an eye drop and an oncology tablet, several with exclusivity. These products usually face fewer competitors than standard oral tablets.

Recent approvals

DateCompanyProductReference brandStatusCompany total
2 Nov 2026LupinAmifampridine tablets, 10 mgFirdapseFirst to file; eligible for 180 day shared exclusivityNot disclosed
5 Nov 2026Alembic PharmaceuticalsOlopatadine ophthalmic solution 0.7% (OTC)Pataday Once Daily ReliefFinal approval248
31 Oct 2026Alembic PharmaceuticalsVenetoclax tablets, 10, 50 and 100 mgVenclextaFirst applicant with Paragraph IV; may be eligible for 180 day exclusivity248
21 Oct 2026Zydus LifesciencesEstradiol and levonorgestrel transdermal systemClimara ProCompetitive Generic Therapy; 180 day exclusivity on launch458
17 Oct 2026Alembic PharmaceuticalsCiprofloxacin and dexamethasone otic suspensionCiprodexFinal approval246
4 Oct 2026Aurobindo PharmaPerampanel tablets, six strengthsFycompaFinal approval599
4 Sep 2026LupinModafinil tablets, 100 and 200 mgProvigilFinal approvalNot disclosed
20 Aug 2026Glenmark PharmaceuticalsFluticasone propionate nasal sprayFlonaseFinal approvalNot disclosed
17 Aug 2026LupinPitolisant tablets, 4.45 and 17.8 mgWakixFinal approvalNot disclosed

Cumulative approvals, as stated by each company

Total USFDA approvals by company
Aurobindo Pharma599
Zydus Lifesciences458
Alembic Pharmaceuticals248
CompanyApprovalsDetailAs of
Aurobindo Pharma599574 final, 25 tentativeOct 2026
Zydus Lifesciences458516 ANDAs filed since FY04Oct 2026
Alembic Pharmaceuticals248229 final, 19 tentativeNov 2026

Company totals include final and tentative approvals as each company reports them. Companies that did not state a running total are not ranked.

Need the numbers behind this tracker?

We profile US generic pipelines, exclusivity windows and competitor filings for pharma clients.

Get the monthly India tracker updateNew state data and new plant announcements in one short email, once a month.

One email a month. Reply to any email to unsubscribe. Privacy policy